Dual Monoclonal Antibody Therapy in Patients with Systemic AL Amyloidosis and Cardiac Involvement

ConclusionsMonoclonal antibodies with distinctly different targets can be safely combined in patients with AL and cardiac involvement. Patients experienced high rates of hematologic and cardiac response with combined anti-CD38 and anti-amyloid monoclonal antibody therapies. Further study of this combined approach is warranted.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

CONCLUSION: Extensive research have been carried out on various process for preparing Bortezomib and composition thereof. This type of dynamic research will clear the path for many generic players in the United States which lead in reduction of price of the composition and thereby enhancing global health care at cheaper prices. PMID: 32234004 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research
Publication date: 4–10 April 2020Source: The Lancet, Volume 395, Issue 10230Author(s): Florent Malard, Mohamad Mohty
Source: The Lancet - Category: General Medicine Source Type: research
17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells. Oncol Rep. 2020 Mar 26;: Authors: Zuo Y, Xu H, Chen Z, Xiong F, Zhang B, Chen K, Jiang H, Luo C, Zhang H Abstract Breast cancer is one of the most common malignancies that threaten the health of women. Although there are a few chemotherapies for the clinical treatment of breast cancer, these therapies are faced with the problems of drug‑resistance and metastasis. Drug combination can help to reduce the adverse side effects of chemotherapies using single drugs, and ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Authors: Allegra A, Innao V, Allegra AG, Pulvirenti N, Pugliese M, Musolino C Abstract Protease inhibitors (PIs) inhibit HIV‑1 and HIV‑2 proteases, impeding virus replication and liberation of viral elements from infected cells. In human immunodeficiency virus (HIV) subjects receiving PI‑based treatment, an impressive decrease in the amount of HIV‑associated cancers, unconnected to viral burden or CD4 amount was observed. Research has reported that PIs have influence on cancer proliferation, spread, and survival as an effect on endoplasmic reticulum stress, proteasome, NF‑κB and Akt signalling....
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Resumo A doen ça de Fabry é definida como uma doença rara de depósito lisossomal ligada ao cromossomo X que apresenta sintomas multissistêmicos, incluindo comprometimento vascular com eventos trombóticos. Paciente do sexo feminino, 57 anos, com diagnóstico de doença de Fabry há 11 anos, apresentava hiper idrose, hipoacusia e angioqueratoma nas mãos. Na história patológica pregressa, relatou episódio de acidente vascular encefálico isquêmico prévio aos 40 anos de idade e trombose arterial crônica agudizada em ...
Source: Jornal Vascular Brasileiro - Category: Surgery Source Type: research
AbstractThese are the results of phase II study of bortezomib-melphalan-prednisolone (VMP) induction therapy followed by lenalidomide-dexamethasone (Rd) consolidation and lenalidomide maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). The primary end point was progression-free survival (PFS). Secondary end points included overall survival (OS), overall response rates (ORRs), and safety. Eighty-three eligible patients were enrolled between October 2012 and August 2014. The median PFS was 28.0  months (95% CI 19.6–36.7) and the median OS was 55.3 months (95% CI 51.6&nd...
Source: Annals of Hematology - Category: Hematology Source Type: research
Condition:   Marginal Zone Lymphoma Intervention:   Sponsor:   International Extranodal Lymphoma Study Group (IELSG) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Venetoclax is a B cell lymphoma 2 (BCL-2) inhibitor active in multiple myeloma, particularly those harboring t(11;14) associated with high BCL-2 expression. Approximately 50% of patients with immunoglobulin light chain (AL) amyloidosis have t (11;14), making venetoclax a suitable agent to consider in this rare disease. We aimed to identify the safety and efficacy of venetoclax in patients with AL amyloidosis.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
Amyloidosis is a rare disease of protein misfolding that results in the deposition of insoluble fibrils mainly in the extracellular spaces of tissues and organs. Currently,> 30 distinct proteins are known to cause amyloidosis in humans.1 Any organ can be involved, although the most clinically relevant are the heart, kidneys, nerves, liver, and gastrointestinal tract.2 Amyloid deposition can be systemic with involvement of multiple organs (eg, monoclonal immunoglobulin light chain amyloidosis [AL]) or can be diffuse involvement of an organ such as the kidneys (eg, lysozyme variants).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
Amyloidosis is a rare disease of protein misfolding that results in the deposition of insoluble fibrils mainly in the extracellular spaces of tissues and organs. There are currently over 30 distinct proteins currently known to cause amyloidosis in humans.1 Any organs can be involved although the most clinically relevant ones are the heart, kidneys, nerves, liver, and gastrointestinal tract.2 Amyloid deposition can be systemic wherein there is involvement of multiple organs (e.g., monoclonal immunoglobulin light chain or AL) or diffuse involvement of an organ like the kidneys (e.g., lysozyme variants or ALys).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
More News: Amyloidosis | Cancer & Oncology | Hematology | Leukemia | Lymphoma | Myeloma | Rare Diseases | Study | Toxicology